CH BIOTECH SER expects a mid-term loss attributable to shareholders to decrease by approximately 59% year-on-year
I'm PortAI, I can summarize articles.
CH BIOTECH SER expects that the loss attributable to shareholders in the middle of 2025 will not exceed HKD 33 million, a year-on-year decrease of approximately 59%. The main reasons include successful implementation of cost control measures, an increase in gross profit margin, a reduction in administrative expenses, and the receipt of approximately HKD 14 million in insurance compensation income
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments